drugset / Trial / NCT04730206
The DAWN Antivirals Trial for Ambulatory COVID-19 Patients
Phase 3
Terminated
44 enrolled
KU Leuven
Universiteit Antwerpen · collabUniversity Ghent · collabUniversité de Liège · collabVrije Universiteit Brussel · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a prospective, placebo controlled, individually randomized controlled phase III trial in Primary Care, assessing the efficacy of antivirals, i.e. camostat and molnupiravir, in accelerating recovery in Covid-19 patients.
Timeline
- Start
- 2021-06-15
- Primary completion
- 2022-07-13
- Completion
- 2022-07-13
Outcome
Outcome not reported
Stopped (Enrollment): “recruitment was too slow”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camostat | Unknown | 200 mg | — |
| Subject | Molnupiravir | Small molecule | 800 mg | — |